Li-Fraumeni Syndrome and the Role of the p53 Tumor Suppressor Gene in Cancer Susceptibility
- 1 March 1998
- journal article
- review article
- Published by Wolters Kluwer Health in Clinical Obstetrics and Gynecology
- Vol. 41 (1) , 172-199
- https://doi.org/10.1097/00003081-199803000-00024
Abstract
Mutation of the tumor suppressor gene p53 is a molecular genetic event frequently observed in human cancer, and inactivating missense mutations usually are accompanied by the resultant overexpression of mutant p53 protein. In gynecologic cancers, p53 is also often altered; the frequency varies depending on types of cancers and where they develop. Further, human papillomavirus oncoproteins that inactivate p53 and Rb proteins play important roles in the development of several gynecologic cancers. Individuals who are heterozygous for germline mutations of the p53 gene are strongly predisposed to a variety of cancers. The identification of these individuals may have profound value in the future when therapies or chemopreventive agents specific for the p53 alteration are available. The role of p53 tumor suppressor gene in gynecologic cancers and heritable cancer susceptibility syndromes including Li-Fraumeni and Lynch II syndromes is an active and important area of study.Keywords
This publication has 97 references indexed in Scilit:
- Regulation of p53 stability by Mdm2Nature, 1997
- Mdm2 promotes the rapid degradation of p53Nature, 1997
- Hereditary cancer: Two hits revisitedZeitschrift für Krebsforschung und Klinische Onkologie, 1996
- Gene-targeting and the p53 tumor-suppressor geneMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1994
- Predictive testing for germline mutations in the p53 gene: Are all the questions answered?European Journal Of Cancer, 1993
- p53 is required for radiation-induced apoptosis in mouse thymocytesNature, 1993
- p53 germline mutations in Li-Fraumeni syndromeThe Lancet, 1991
- The p53 tumour suppressor geneNature, 1991
- Adenocarcinoma of the small bowel in Lynch syndrome IICancer, 1989
- TRANSMISSION OF IN-VITRO RADIORESISTANCE IN A CANCER-PRONE FAMILYThe Lancet, 1981